Amigrenin, 50 mg 6 pcs

Antimigraine drug. Specific selective agonist of serotonin 5HT1B-1D-receptors (5-hydroxytryptamine-1-like), located mainly in the smooth muscle of the walls of blood vessels of the brain.

Stimulation of 5HT1-receptors leads to selective vasoconstriction in the carotid artery system and reduction of neurogenic inflammation processes without significant effect on cerebral blood flow.

In addition, sumatriptan has been experimentally shown to inhibit trigeminal nerve activity.

These effects are thought to help reduce the severity of pain in migraine.

The clinical effect is noted 30 min after oral administration of the drug.

Indications

– control of acute migraine attacks with or without aura.

Active ingredient

Composition

1 tablet sumatriptan (in the form of succinate) 0.05 g

Supplementary substances:

MCC;

Milk sugar;

Potato starch;

br>

sodium carboxymethyl starch;

magnesium stearate;

p> oxypropyl cellulose or oxypropyl methyl cellulose;

PVP;

polyethylene glycol 4000;

talk;

titanium dioxide

How to take, the dosage

Amigrenin is not intended for prophylactic use.

Adults are prescribed in a single dose of 50 mg, in some cases 100 mg. The maximum daily dose is 300 mg.

If migraine symptoms do not disappear or decrease after the first dose of Amigrenin, the drug should not be repeated to stop an ongoing attack. If symptoms decrease or subside and then resume, a second dose may be taken within the next 24 hours. The interval between doses should be at least 2 h.

Interaction

In concomitant administration with ergotamine, prolonged vasospasm was noted. Amigrenin may be administered not earlier than 24 h after taking ergotamine-containing drugs.

Possible interaction between sumatriptan and MAO inhibitors, their simultaneous use is contraindicated.

There have been isolated reports of weakness, hyperreflexia, and impaired coordination in patients after concomitant administration of sumatriptan and selective serotonin reuptake inhibitors. Amigrenin and drugs of this group should not be prescribed simultaneously.

Amigrenin and lithium preparations should not be prescribed concomitantly.

Special Instructions

Sumatriptan should be administered with particular caution in epilepsy (including any condition with decreased seizure threshold), as well as in patients with controlled arterial hypertension.

When prescribing Amigrenin in patients with newly diagnosed migraine or with migraine with atypical symptoms, other potentially dangerous neurological diseases should be excluded. It should be borne in mind that in patients with migraine there is a risk of cerebrovascular complications (including stroke or transient cerebrovascular disorders).

The drug should not be administered to patients at risk of cardiovascular pathology without prior examination to rule out the disease. The first 2 to 3 doses of the drug should be taken under the supervision of a physician (because coronary artery spasm is possible).

In patients with hypersensitivity to sulfonamides when taking sumatriptan allergic reactions are possible, which range from skin manifestations to anaphylactic shock.

If there is no effect on the first dose, the diagnosis should be clarified.

The clinical experience with the drug in patients over 65 years of age is limited (there is no significant difference in pharmacokinetics compared to younger patients).

Influence on driving and operating ability

Drowsiness may occur with sumatriptan therapy. Therefore, during the period of the drug use the patients should be particularly careful to drive vehicles and engage in other potentially dangerous activities requiring high speed of psychomotor reactions.

Contraindications

– hemiplegic, basilar and ophthalmoplegic forms of migraine;

– CHD (including angina pectoris);

– peripheral artery occlusive disease;

– uncontrolled arterial hypertension;

– stroke or transient cerebral circulation disorder (including history);

– significant impairment of liver function;

– concomitant use of drugs containing ergotamine or its derivatives;

– concomitant use of MAO inhibitors and up to 14 days after their withdrawal;

– pregnancy;

– lactation (breastfeeding) period;

– patients under 18 years of age and over 65 years of age;

– hypersensitivity to the drug.

Side effects

Cardiovascular system disorders:hyperemia of skin and mucous membranes, arterial hypotension, tachycardia, palpitations, angina pectoris attack, transient BP increase, transient ECG changes of ischemic type, bradycardia; in single cases – manifestations of Raynaud’s syndrome.

CNS side:dizziness, weakness, drowsiness, fatigue; visual disorders (diplopia, scotoma, decreased visual acuity).

Digestive system disorders:A feeling of discomfort in the stomach, dysphagia, nausea, vomiting; rarely – ischemic colitis, increased liver enzyme activity.

Allergic reactions:rash, itching, erythema, urticaria, anaphylaxis.

Other:possible tingling sensations, heat, heaviness, pressure or compression in various parts of the body, myalgia.

Overdose

Treatment:In case of overdose, the patient should be observed for 10 h, administering symptomatic therapy as needed.

Similarities